Press Releases on Buchanan Communications:
|
 |
| Oxford Biomedica Announces Appointment Of Chief Medical Officer |
1st September, 2005 |
Oxford Biomedica |
Oxford
Biomedica Announces Appointment Of Chief Medical Officer
Oxford, UK: 7 September 2005
–
Oxford BioMedica
(LSE:OXB.L), the
|
| Cobra and Auxilium Announce Extension of Agreement to Manufacture AA4500
|
1st August, 2005 |
Cobra |
Cobra and Auxilium
Announce Extension of Agreement to Manufacture AA4500 for Auxilium
Pharmaceuticals, Inc.
|
| OXFORD BIOMEDICA SUCCESSFULLY COMPLETES STAGE ONE OF THE PHASE II TRIAL
|
1st August, 2005 |
Oxford Biomedica |
OXFORD
BIOMEDICA SUCCESSFULLY COMPLETES STAGE ONE OF THE PHASE II TRIAL WITH METXIA
IN PANCREATIC CANCER
Oxford,
UK: 1 August 2005
|
| Oxford Biomedica Is Granted Key Lentivector® Patents In China |
1st July, 2005 |
Oxford Biomedica |
Oxford Biomedica Is Granted Key
Lentivector® Patents In China
Oxford, UK: 4 July 2005 – Oxford
BioMedica (LSE: OXB), the leading gene therapy company, announced today that the
Patent
|
| Oxford Biomedica Presents Encouraging Innurex Preclinical Efficacy Data
|
1st June, 2005 |
Oxford Biomedica |
Oxford Biomedica Presents
Encouraging Innurex Preclinical Efficacy Data In Spinal Cord Injury
- Presentation at
the 8th Annual Meeting of the American Society of Gene Therapy, 1-5
|
This page has been viewed 234 times since April 2007, the link to the organisation's website has been followed 46 times